{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"3.200","floor":"2.550"},"ipodate":{"start":"2019-05-17 00:00:00","end":"2019-05-22 00:00:00"},"minimumcapital":"6464.49","subscribed":"91.70","marketcap":"64.24億","H_marketcap":"--","pe":"73.06","codesrate":"50.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01521/LTN20190517022_C.pdf","ipopricing":"3.200","resultdate":"2019-05-29 00:00:00","enddate":"2019-05-22 00:00:00","listeddate":"2019-05-30 00:00:00","issuenumber":"50191.00萬","issuenumberhK":"20076.40萬","issuenumberother":"30114.60萬","grayprice":"3.70","sponsors":"美林遠東有限公司,高盛(亞洲)有限責任公司","raisemoney":"151541.00萬","use":"1、預計于上市后12至18個月內將所分配金額約272百萬港元（或所得款項凈額的約20%）用于以下預期開支：\n（1）約81百萬港元的款項將用于改善、升級及擴大我們位于美國的現有設施；\n（2）約46百萬港元的款項將用于我們計劃于中國上海張江高科技園租賃的總建筑面積約為40,000至50,000平方呎的新設施的翻新；\n（3）約39百萬港元的款項將用于改善本集團于美國及中國運營的系統、流程及應用程式；\n（4）約106百萬港元的款項將用于為我們的設施購買新設備及技術，以及于美國及中國聘請更多科學家；\n2、約545百萬港元的款項（或所得款項凈額的約40%）于上市后12至18個月內將用于有機地擴大及拓寬我們的能力及服務范圍；\n3、約408百萬港元的款項（或所得款項凈額的約30%）將用于通過潛在收購；\n4、約136百萬港元的款項（或所得款項凈額的約10%）將用作為營運資金及一般企業用途，包括（尤其是）改善我們業務的常規制度、經營及流程。","shares":2000,"leadagent":"","bookrunners":"美林遠東有限公司,高盛(亞洲)有限責任公司,中信里昂證券有限公司,海通國際證券有限公司","coordinator":"美林遠東有限公司,高盛(亞洲)有限責任公司,中信里昂證券有限公司,海通國際證券有限公司","firstDayOpen":"3.68","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"美林遠東有限公司","code":"E01521","name":"方達控股","fullname":"方達控股公司"},"institutioninfo":{"principaloffice":"香港皇后大道東183號合和中心54樓","registrars":"卓佳證券登記有限公司","registrarstel":"(852)2980 1333","chairman":"李志和","secretary":"張盈倫","telephone":"(610)232 0100","substantialshareholders":"香港泰格醫藥科技有限公司(51.45%)","principalactivities":"公司是快速增長的合同研究機構，提供貫穿整個藥物發現和開發過程的一體化、科學驅動的研究、分析和開發服務，協助醫藥公司實現藥物開發目標。","website":"www.frontagelab.com"},"managerinfo":[{"managername":"李志和","post":"董事長、行政總裁兼執行董事","rankno":1},{"managername":"高峻","post":"非執行董事","rankno":2},{"managername":"李軼梵","post":"獨立非執行董事","rankno":3}],"investorinfo":[{"institutionname":"Hillhouse Funds","shareholding":"122,632,000.0","percentage":24.4,"ReleaseDate":"2019-11-30 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"景林資產管理有限公司","shareholding":"49,052,000.0","percentage":9.8,"ReleaseDate":"2019-11-30 00:00:00","relatedparty":"Greenwoods Asset Management Holdings Limited","subsidiary":["景林資產管理有限公司","景林資產管理香港有限公司"],"InverstorType":"公司"},{"institutionname":"Worldwide Healthcare Trust PLC","shareholding":"36,788,000.0","percentage":7.3,"ReleaseDate":"2019-11-30 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"}],"TotalShareholdingPercentage":41.5},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":509}